Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Fifty Day Moving Average – Should You Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $13.90 and traded as low as $8.21. Seres Therapeutics shares last traded at $8.65, with a volume of 58,265 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MCRB. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Trading Up 6.0%

The business has a fifty day simple moving average of $13.90 and a two-hundred day simple moving average of $16.52. The company has a market cap of $78.28 million, a PE ratio of -2.42 and a beta of 0.22.

Institutional Trading of Seres Therapeutics

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Seres Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock valued at $1,282,000 after acquiring an additional 1,160 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 3,918 shares during the last quarter. State Street Corp increased its holdings in shares of Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 4,170 shares during the last quarter. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 4.8% during the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after buying an additional 4,723 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.